Cardio Diagnostics Showcases AI-Powered Cardiovascular Solutions at Major Benefits Conferences

Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes. To view the full press release, visit https://ibn.fm/qFRHu.

The conferences provide a platform for Cardio Diagnostics to demonstrate how its technology can transform cardiovascular disease prevention and management. Cardiovascular disease remains the leading cause of death globally and a significant driver of healthcare expenditures in the United States. By leveraging artificial intelligence and integrated genetic-epigenetic analysis, Cardio Diagnostics aims to shift the paradigm from reactive treatment to proactive prevention. The company's solutions, such as PrecisionCHD(TM), offer personalized risk assessments that can guide early interventions, potentially reducing the incidence of heart attacks, strokes, and other costly complications.

For benefits decision-makers, the implications are substantial. The HeartRisk(TM) population insights platform enables employers and plan administrators to identify high-risk groups within their workforce, allowing targeted wellness programs and resource allocation. This can lead to lower healthcare premiums, reduced absenteeism, and improved employee productivity. As healthcare costs continue to rise, innovative approaches like those offered by Cardio Diagnostics become increasingly critical.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.